Kangle Guard

Kangle Guard is a clinical-stage biotechnology company based in China that specializes in the development of recombinant protein vaccines. The company's lead programs include trivalent and nonavalent human papillomavirus (HPV) vaccines, which are currently in Phase 3 clinical trials for both female and male populations. Kangle Guard utilizes its proprietary virus-like particle (VLP) technology to design vaccines targeting a range of infectious diseases, including norovirus, respiratory syncytial virus (RSV), and shingles. With a large-scale manufacturing base in Kunming, the company aims to provide affordable, high-quality prophylactic solutions to the global market. Kangle Guard is listed on the Beijing Stock Exchange and is a key player in the domestic Chinese vaccine industry, notably being among the first to advance a nonavalent HPV vaccine into late-stage trials for men.